Alnylam Pharmaceuticals, Inc. ALNY
We take great care to ensure that the data presented and summarized in this overview for ALNYLAM PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ALNY
View all-
Capital World Investors Los Angeles, CA16.5MShares$4.05 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$3.1 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.34 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.29 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$1.22 Billion0.24% of portfolio
-
Baillie Gifford & CO4.89MShares$1.2 Billion1.03% of portfolio
-
Capital International Investors Los Angeles, CA3.97MShares$975 Million0.22% of portfolio
-
Dodge & Cox San Francisco, CA3.62MShares$889 Million0.6% of portfolio
-
State Street Corp Boston, MA3.47MShares$851 Million0.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.45MShares$847 Million0.11% of portfolio
Latest Institutional Activity in ALNY
Top Purchases
Top Sells
About ALNY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at ALNY
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 12
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
1,752
-1.49%
|
$439,752
$251.62 P/Share
|
Nov 27
2024
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
1,531
-2.75%
|
$385,812
$252.59 P/Share
|
Nov 26
2024
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
1,469
-1.9%
|
$367,250
$250.35 P/Share
|
Nov 26
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,469
-2.07%
|
$367,250
$250.35 P/Share
|
Nov 26
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,682
-1.06%
|
$420,500
$250.35 P/Share
|
Nov 26
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
1,682
-1.81%
|
$420,500
$250.35 P/Share
|
Nov 26
2024
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,219
-1.27%
|
$1,304,750
$250.35 P/Share
|
Nov 25
2024
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+15.89%
|
-
|
Nov 25
2024
|
Tolga Tanguler EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+16.99%
|
-
|
Nov 25
2024
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,434
+9.6%
|
-
|
Nov 25
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
3,434
+15.21%
|
-
|
Nov 25
2024
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,658
+11.25%
|
-
|
Oct 08
2024
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
96
+0.61%
|
-
|
Oct 01
2024
|
Robert W. Hesslein EVP, CLO and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
7,245
+50.0%
|
-
|
Aug 20
2024
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,000
-16.96%
|
$4,200,000
$280.0 P/Share
|
Aug 20
2024
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+14.5%
|
$1,275,000
$85.0 P/Share
|
Aug 12
2024
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
22,025
-14.64%
|
$5,968,775
$271.83 P/Share
|
Aug 12
2024
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
BUY
Exercise of conversion of derivative security
|
Direct |
20,725
+26.47%
|
$1,885,975
$91.36 P/Share
|
Aug 06
2024
|
Dennis A Ausiello Director |
SELL
Open market or private sale
|
Direct |
20,250
-46.12%
|
$5,305,500
$262.79 P/Share
|
Aug 06
2024
|
Dennis A Ausiello Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,250
+40.16%
|
$2,389,500
$118.24 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 220K shares |
---|---|
Grant, award, or other acquisition | 130K shares |
Open market or private sale | 249K shares |
---|